Eagle Strategies LLC Decreases Stake in Pfizer Inc. (NYSE:PFE)

Eagle Strategies LLC decreased its position in Pfizer Inc. (NYSE:PFEFree Report) by 30.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,360 shares of the biopharmaceutical company’s stock after selling 4,003 shares during the quarter. Eagle Strategies LLC’s holdings in Pfizer were worth $271,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Cornerstone Wealth Management LLC lifted its position in Pfizer by 19.4% during the first quarter. Cornerstone Wealth Management LLC now owns 63,545 shares of the biopharmaceutical company’s stock valued at $1,763,000 after purchasing an additional 10,314 shares during the last quarter. First Trust Direct Indexing L.P. raised its position in shares of Pfizer by 45.0% during the 1st quarter. First Trust Direct Indexing L.P. now owns 51,735 shares of the biopharmaceutical company’s stock valued at $1,436,000 after buying an additional 16,060 shares in the last quarter. Accel Wealth Management bought a new position in shares of Pfizer in the 1st quarter valued at about $205,000. American National Bank & Trust Co. VA purchased a new position in Pfizer in the first quarter worth about $285,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Pfizer during the first quarter worth approximately $315,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of PFE stock opened at $28.52 on Thursday. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $31.54. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The stock has a fifty day simple moving average of $29.06 and a two-hundred day simple moving average of $28.56. The stock has a market capitalization of $161.61 billion, a price-to-earnings ratio of 38.54, a P/E/G ratio of 0.99 and a beta of 0.67.

Pfizer (NYSE:PFEGet Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.17) earnings per share. On average, analysts predict that Pfizer Inc. will post 2.67 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.89%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PFE. Sanford C. Bernstein initiated coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. Barclays lifted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Wells Fargo & Company upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.58.

View Our Latest Stock Analysis on PFE

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.